Megestrol Acetate is a synthetic progestin derived from progesterone. It is a hormonal pharmaceutical ingredient with progestational activity and is used in pharmaceutical formulations for specific hormone-dependent conditions. It is also used to help manage anorexia and cachexia associated with cancer or AIDS.
Megestrol Acetate is a specialized hormonal pharmaceutical API used in the development and manufacture of oral pharmaceutical formulations.
Important quality attributes include identity, assay, related substances, water content, residual solvents, residue on ignition, specific optical rotation and elemental impurities, according to the applicable API specification.
CAS Number: 595-33-5
Molecular Formula: C24H32O4
Molecular Weight: 384.52 g/mol
Chemical Name: Megestrol Acetate
Drug Class: Progestin
Therapeutic Class: Hormonal Agent / Appetite Stimulant
Therapeutic Area: Oncology / Hormonal Therapy
Molecule Type: Synthetic Steroidal Compound
Megestrol Acetate is a synthetic progestational agent that binds to progesterone receptors and produces progesterone-like effects.
Its pharmacological activity is associated with:
Megestrol Acetate API is used in pharmaceutical development for:
Megestrol Acetate is commonly formulated as:
Megestrol Acetate is generally described as a white to off-white crystalline powder. Its physical and solid-state characteristics should be controlled according to the applicable API specification.
A controlled Megestrol Acetate API manufacturing process may involve:
Typical Megestrol Acetate API testing may include:
Store Megestrol Acetate API in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive moisture, heat and direct light.
Megestrol Acetate is relevant to research involving:
Megestrol Acetate is a synthetic progestin pharmaceutical API with CAS Number 595-33-5, molecular formula C24H32O4, and molecular weight 384.52 g/mol. It is primarily used in oral pharmaceutical formulations and is associated with appetite stimulation and management of anorexia and cachexia in selected clinical settings.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 1.0% |
| Individual Impurity | NMT 1.0% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |